论文部分内容阅读
目的:观察为耐药结核病患者联合应用胸腺肽、抗结核药物治疗的临床效果。方法:选取2010年06月~2012年06月108例我院收治的耐药结核病患者,按随机数字表法将其分成实验组58例,对照组50例,对照组应用以异烟肼为主的抗痨药物治疗,实验组联合应用胸腺肽、抗结核药物治疗,比较临床疗效。结果:与对照组相比,实验组耐药结核病患者的治疗效果更佳,实验组痰菌转阴率、治愈率、病灶吸收好转率、总有效率为86.2%、81.0%、8.6%、89.7%,以上观察指标均优于对照组。结论:胸腺肽联合抗结核药物治疗耐药结核病患者,效果显著,值得在临床应用、推广。
Objective: To observe the clinical effect of combination of thymosin and antituberculosis drugs for drug-resistant tuberculosis patients. Methods: From June 2010 to June 2012, 108 cases of drug-resistant TB patients admitted to our hospital were divided into experimental group (58 cases) and control group (50 cases) by random number table method. The control group was given isoniazid Anti-tuberculosis drug treatment, the experimental group combined thymosin, anti-TB drug treatment, the clinical efficacy. Results: Compared with the control group, the treatment group had better therapeutic effect in patients with drug-resistant TB, and the total effective rate was 86.2%, 81.0%, 8.6%, 89.7 %, The above indicators are better than the control group. Conclusion: Thymosin combined with anti-TB drugs in the treatment of drug-resistant tuberculosis patients, the effect is significant, it is worth in clinical application, promotion.